Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract

Inflammatory Bowel Diseases Clinical Trial

Official title:

Value of Fecal Calprotectin in Upper Gastrointestinal Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00920400
• Other study ID #: CALPROTECT
• Status: Completed
• Phase: N/A
• First received: June 12, 2009
• Last updated: January 11, 2010
• Start date: March 2008
• Est. completion date: December 2009

Study information

• Verified date: January 2010
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Observational

Clinical Trial Summary

Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 287
• Est. completion date: December 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients referred for upper gastrointestinal endoscopy for any reason

• Older than 18 years

Exclusion Criteria:

• Patients who are not able to provide informed consent

• Patients who are not able to provide a stool sample

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Esophagitis
• Esophagitis, Peptic
• Functional Dyspepsia
• Inflammatory Bowel Diseases
• Irritable Bowel Syndrome
• Peptic Esophagitis
• Peptic Ulcer

Locations

Country	Name	City	State
Switzerland	Department of Gastroenterology & Hepatology	Basel	Basel-Stand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland,